Skip to main content

Nanocarriers for Transmucosal Vaccine Delivery

Buy Article:

$63.00 plus tax (Refund Policy)


Immunization has been realized as one of the most cost effective methods of controlling microbial infections. Currently, the most widely employed means of vaccine delivery includes intramuscular injection which is effective against pathogens invading via the systemic route. The antibody titers do not extend to mucosal or serosal sites which are also the portals of entry for invading pathogens. Mucosal means of delivery comes as viable alternatives. The oral route for mucosal vaccination has not been successful in presenting antigens to the body. Acidic environment and inactivating enzymes of the GI tract degrade the antigen before it is presented to the M-cells of Peyer's patches. Nanocarrier based vaccines however, can help to overcome the problems associated with mucosal delivery. These carriers have shown to improve the bioavailability, act as adjuvant to provoke a stronger immune response while being targeted to associated tissues, leading to improved success of vaccination which inculcates interest of nanotechnology in vaccination. This review encompasses a wide range of nanocarriers that have been of interest.

Keywords: Gut associated lymphoid tissues (GALT); IgG antibodies; Mucosal vaccination; antigenic substance; mucosal immunity; nanocarriers; nanoparticles; novel drug delivery systems; vaccine delivery

Document Type: Research Article


Publication date: 2011-04-01

More about this publication?
  • Current Nanoscience publishes authoritative reviews and original research reports, written by experts in the field on all the most recent advances in nanoscience and nanotechnology. All aspects of the field are represented including nano- structures, synthesis, properties, assembly and devices. Applications of nanoscience in biotechnology, medicine, pharmaceuticals, physics, material science and electronics are also covered. The journal is essential to all involved in nanoscience and its applied areas.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more